Denemek ALTIN - Özgür
Rare diseases policy outlines challenges sans solutions
Bio Spectrum
|June 2021
There is no substantial data on the number of people suffering from rare diseases in India and the data that is available is from tertiary care hospitals. The lack of epidemiological data on rare diseases makes it a herculean task to determine the prevalence and burden of rare diseases, hence hampering the definition of rare diseases in the Indian context.
The National Policy for Treatment of Rare Diseases (NPTRD) was formulated by the Ministry of Health and Family Welfare (MoH&FW), Government of India in July, 2017. The policy, however, has faced challenges with implementation. One of them was bringing the states on board and the lack of clarity on the quantum of support for the states from the Centre in terms of tertiary care.
Due to these challenges, an Expert Committee was constituted by MoH&FW in November, 2018 to review the NPTRD, 2017. The Expert Committee, along with the approval of the competent authority, finalised a draft of the National Policy for Rare Diseases and placed it in the public domain on January 13, 2020 for all stakeholders to review and recommend. Reviews and recommendations were examined by an Expert Committee set up by the Directorate General of Health Services (DGHS). It has finalised the policy after further deliberations, examination of recommendations. There are between 7000 and 8000 rare diseases, but less than 5 per cent have therapies available to treat them. About 95 per cent rare diseases have no approved treatment and less than 1 in 10 patients receive disease-specific treatment. Where drugs are available, they are prohibitively expensive, placing immense strain on the resources.
Rampant delayed diagnosis
Bu hikaye Bio Spectrum dergisinin June 2021 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
Bio Spectrum'den DAHA FAZLA HİKAYE
Bio Spectrum
Building Breakthrough Medical Devices
Dr Ria Khurana founded RNT Health Insights, a Chandigarh-based healthtech startup specialising in Al-assisted diagnostic solutions for the accurate detection of pathologies during endoscopic procedures, in 2022 along with Dr Tanmaya Gulati.
2 mins
January 2026
Bio Spectrum
Bridging classical epidemiology with modern science
A physician scientist with a MBBS from Lady Hardinge Medical College, (University of Delhi), a post-graduation in Paediatrics and a PhD from All India Institute of Medical Sciences (AIIMS), New Delhi, Prof.Shinjini Bhatnagar served as Professor of Eminence at Translational Health Science and Technology Institute (THSTI) until February 2023 and was subsequently appointed Distinguished Professor at THSTI until May 2025.
2 mins
January 2026
Bio Spectrum
"AI, Automation & Analytics: A new era of modern microbiology testing!"
Pharmaceutical manufacturing is undergoing a paradigm shift.
4 mins
January 2026
Bio Spectrum
The CRISPR Moment
CRISPR (clustered regularly interspaced short palindromic repeats) technology is ushering in a new era of gene and cell therapy, offering more precision and potential for treating genetic disorders, cancer, and infectious diseases.
2 mins
January 2026
Bio Spectrum
Leveraging Microfluidic Technology for mRNA-LNP Manufacturing
Over the past five years, messenger RNA (mRNA) therapeutics have evolved from experimental concepts into lifesaving medicines.
2 mins
January 2026
Bio Spectrum
Demonstrating India's Vaccine Capabilities
Havisure is India's first and only indigenously developed Hepatitis A vaccine, to address one of the country's most persistent public health challengeswidespread Hepatitis A infections caused by inadequate sanitation and contaminated food and water.
2 mins
January 2026
Bio Spectrum
Inspiring Future Generations
A PhD in molecular biology from the University of Cambridge, UK, Prof. Gaiti Hasan is a Distinguished Fellow at the National Centre for Biological Sciences (NCBS), Bengaluru.
2 mins
January 2026
Bio Spectrum
A Landmark for India's Antibiotic Innovation
After three decades of research and hard work, India has led the way with the creation of Nafithromycin, the country's first indigenous antibiotic.
2 mins
January 2026
Bio Spectrum
"Future vaccine innovation will be integration of R&D, regulatory support and manufacturing”
TechInvention Lifecare Limited, a vaccine focused biotechnology company headquartered in Mumbai, is recognised for its innovative contributions to global healthcare.
4 mins
January 2026
Bio Spectrum
Telangana: Building India's Most Credible Life Sciences Ecosystem
Telangana's recognition as BioSpectrum India's Best Performing State in Life Sciences 2025 is a timely validation of the direction the state has taken in recent years-one anchored in execution, responsiveness, and a clear understanding of where global life sciences value chains are headed.
4 mins
January 2026
Translate
Change font size

